Axsome Therapeutics (AXSM) Scheduled to Post Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSM) will issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($1.36) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 5th. The company reported ($1.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.06. Axsome Therapeutics had a negative net margin of 105.85% and a negative return on equity of 117.46%. The company had revenue of $87.17 million during the quarter, compared to analyst estimates of $84.53 million. On average, analysts expect Axsome Therapeutics to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Axsome Therapeutics Price Performance

AXSM opened at $87.25 on Tuesday. The company has a debt-to-equity ratio of 1.77, a quick ratio of 2.40 and a current ratio of 2.48. The stock’s 50 day moving average price is $90.19 and its 200-day moving average price is $83.07. The stock has a market capitalization of $4.14 billion, a PE ratio of -13.40 and a beta of 1.26. Axsome Therapeutics has a 52-week low of $55.02 and a 52-week high of $98.40.

Insider Buying and Selling at Axsome Therapeutics

In other news, Director Mark E. Saad sold 11,016 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the transaction, the director now owns 10,002 shares in the company, valued at $913,282.62. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Mark E. Saad sold 11,016 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the sale, the director now directly owns 10,002 shares of the company’s stock, valued at $913,282.62. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Mark L. Jacobson sold 47,739 shares of the stock in a transaction on Friday, August 9th. The shares were sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the transaction, the chief operating officer now owns 5,783 shares of the company’s stock, valued at $487,275.58. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 22.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AXSM shares. Bank of America upgraded shares of Axsome Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $95.00 to $106.00 in a research report on Tuesday, August 6th. Wells Fargo & Company assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, September 3rd. They issued an “overweight” rating and a $140.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $130.00 price target on shares of Axsome Therapeutics in a report on Thursday, September 5th. Royal Bank of Canada lifted their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $107.00 target price on shares of Axsome Therapeutics in a research report on Monday, September 16th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $124.64.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.